Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 7:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,815 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sarcoma Clear all
Recruiting Phase 1 Interventional

Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma

NCT07144254
View directory record Official record
Conditions
Osteosarcoma Recurrent, Osteosarcoma in Children, Relapsed Osteosarcoma, Refractory Osteosarcoma
Interventions
Tegavivint, Gemcitabine
Drug
Lead sponsor
Emory University
Other
Eligibility
1 Year to 30 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 4, 2026, 7:33 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

NCT04458922
View directory record Official record
Conditions
Central Chondrosarcoma, Grade 2, Central Chondrosarcoma, Grade 3, Dedifferentiated Chondrosarcoma, Metastatic Clear Cell Sarcoma of Soft Tissue, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
14
States / cities
Los Angeles, California • Gainesville, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 4, 2026, 7:33 PM EDT
Completed No phase listed Observational

Effects of Potent Antiretroviral Therapy on Kaposi s Sarcoma

NCT00006171
View directory record Official record
Conditions
HIV Seropositivity, Kaposi's Sarcoma, HIV Infections
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
13 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 4, 2026, 7:33 PM EDT
Recruiting Phase 1 Interventional

Palbociclib and Pembrolizumab in Sarcoma

NCT06113809
View directory record Official record
Conditions
Sarcoma
Interventions
Palbociclib, Pembrolizumab
Drug
Lead sponsor
John Rieth
Other
Eligibility
12 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 4, 2026, 7:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

NCT00964821
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions
trivalent influenza vaccine, Immunoenzyme technique, Laboratory biomarker analysis
Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Sep 4, 2026, 7:33 PM EDT
Completed Not applicable Interventional

WeCanManage. An mHealth Self-management Tool

NCT06185738
View directory record Official record
Conditions
Breast Cancer, Head and Neck Cancer, Sarcoma
Interventions
WCM app
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 4, 2026, 7:33 PM EDT
Terminated Phase 1 Interventional

NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

NCT03399448
View directory record Official record
Conditions
Multiple Myeloma, Melanoma, Synovial Sarcoma, Myxoid/Round Cell Liposarcoma
Interventions
NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1, Cyclophosphamide, Fludarabine, NY-ESO-1 expression testing
Biological · Drug · Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 4, 2026, 7:33 PM EDT
Active, not recruiting Not applicable Interventional

Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors

NCT00580385
View directory record Official record
Conditions
Osteosarcoma
Interventions
Tissue Procurement
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
763 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 4, 2026, 7:33 PM EDT
Completed Phase 1 Interventional

Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors

NCT00002543
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
gallium nitrate
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2004
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Sep 4, 2026, 7:33 PM EDT
Completed Not applicable Interventional

Nurse-Driven Telephone Intervention in Improving Side Effects in Cancer Patients Undergoing Chemotherapy

NCT03964896
View directory record Official record
Conditions
Breast Carcinoma, Head and Neck Carcinoma, Sarcoma
Interventions
Survey, Survey Administration, Telephone-Based Intervention
Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Sep 4, 2026, 7:33 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery

NCT03074318
View directory record Official record
Conditions
Metastatic Leiomyosarcoma, Metastatic Liposarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma
Interventions
Avelumab, Trabectedin
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 4, 2026, 7:33 PM EDT
Completed Phase 3 Interventional

Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.

NCT00002147
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Doxorubicin hydrochloride (liposomal)
Drug
Lead sponsor
Sequus Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 4, 2026, 7:33 PM EDT
Recruiting No phase listed Observational

Localized Leiomyosarcoma Biomarker Protocol

NCT04925089
View directory record Official record
Conditions
Leiomyosarcoma
Interventions
Blood and Tissue collection
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 4, 2026, 7:33 PM EDT
Completed Phase 2 Interventional Results available

Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma

NCT02097238
View directory record Official record
Conditions
Recurrent Osteosarcoma
Interventions
Eribulin Mesylate, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 49 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
116
States / cities
Birmingham, Alabama • Phoenix, Arizona • Downey, California + 76 more
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Sep 4, 2026, 7:33 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer

NCT00562185
View directory record Official record
Conditions
Ovarian Cancer
Interventions
carboplatin, doxorubicin hydrochloride
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2017 · Synced Sep 4, 2026, 7:33 PM EDT
Terminated Not applicable Interventional

EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

NCT00087191
View directory record Official record
Conditions
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor, Localized Extrahepatic Bile Duct Cancer, Localized Gallbladder Cancer, Localized Gastrointestinal Carcinoid Tumor, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Primary Peritoneal Cavity Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Adult Soft Tissue Sarcoma, Recurrent Colon Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Small Intestine Cancer, Recurrent Uterine Sarcoma, Regional Gastrointestinal Carcinoid Tumor, Small Intestine Adenocarcinoma, Small Intestine Leiomyosarcoma, Small Intestine Lymphoma, Stage 0 Non-small Cell Lung Cancer, Stage I Adult Soft Tissue Sarcoma, Stage I Colon Cancer, Stage I Gastric Cancer, Stage I Non-small Cell Lung Cancer, Stage I Ovarian Epithelial Cancer, Stage I Ovarian Germ Cell Tumor, Stage I Pancreatic Cancer, Stage I Rectal Cancer, Stage I Uterine Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage II Colon Cancer, Stage II Gastric Cancer, Stage II Non-small Cell Lung Cancer, Stage II Ovarian Epithelial Cancer, Stage II Ovarian Germ Cell Tumor, Stage II Pancreatic Cancer, Stage II Rectal Cancer, Stage II Uterine Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Colon Cancer, Stage III Gastric Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Uterine Sarcoma, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adult Soft Tissue Sarcoma, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Uterine Sarcoma, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
EF5, motexafin lutetium, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Sep 4, 2026, 7:33 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors

NCT04681248
View directory record Official record
Conditions
Esophageal Neoplasm, Adenocarcinoma of the Gastroesophageal Junction, GastroEsophageal Cancer, Squamous Cell Carcinoma, Gastric Adenocarcinoma, Endometrial Cancer, Uterine Cancer, Ovarian Cancer, Carcinosarcoma, Gastric Cancer
Interventions
DKN-01
Drug
Lead sponsor
Leap Therapeutics, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 4, 2026, 7:33 PM EDT
Recruiting No phase listed Observational

International Rare Brain Tumor Registry

NCT05697874
View directory record Official record
Conditions
Astroblastoma, BCOR ITD Sarcoma, CNS Sarcoma, Unclassified Tumor, Malignant
Interventions
Not listed
Lead sponsor
Children's National Research Institute
Other
Eligibility
Up to 45 Years
Enrollment
5,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 4, 2026, 7:33 PM EDT
Completed Phase 1 Interventional

Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors

NCT02644460
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Brain Tumor, Recurrent, Solid Tumor, Recurrent, Neuroblastoma, Recurrent, Refractory, Ewing Sarcoma, Recurrent, Refractory, Rhabdomyosarcoma, Recurrent, Refractory, Osteosarcoma, Recurrent, Refractory, Rhabdoid Tumor, Recurrent, Refractory
Interventions
Abemaciclib
Drug
Lead sponsor
Emory University
Other
Eligibility
2 Years to 25 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
4
States / cities
Phoenix, Arizona • Aurora, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 4, 2026, 7:33 PM EDT
Recruiting Not applicable Interventional

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

NCT04199026
View directory record Official record
Conditions
Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma
Interventions
Doxorubicin, Doxorubicin Hydrochloride, Drug Delivery Microdevice, Everolimus, Ganitumab, Ifosfamide, Irinotecan, Pazopanib, Polyethylene Glycol, Temozolomide, Temsirolimus, Therapeutic Conventional Surgery, Vincristine
Drug · Device · Biological + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
10 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 4, 2026, 7:33 PM EDT
Completed Phase 1 Interventional

Phase I Study of Weekly Oral VP-16 for AIDS-Associated Kaposi's Sarcoma

NCT00000660
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Etoposide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
6
States / cities
San Francisco, California • New York, New York • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 4, 2026, 7:33 PM EDT
Not listed Phase 1 Interventional

Monoclonal Antibody Therapy in Treating Patients With Recurrent Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

NCT00004858
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
B43-genistein immunoconjugate
Biological
Lead sponsor
Parker Hughes Cancer Center
Other
Eligibility
Up to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
3
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Sep 4, 2026, 7:33 PM EDT
Terminated Phase 4 Interventional Results available

Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis

NCT00924950
View directory record Official record
Conditions
Plaque Psoriasis, Psoriasis Vulgaris
Interventions
Taclonex Ointment and Hydrogel Patch, Taclonex Ointment
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Sep 4, 2026, 7:33 PM EDT